Eloxx Pharmaceuticals, Inc. (ELOX) shareholders
Close on Nov 17, 2026Market cap $79.70MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Coastlands Capital GP LLC Joint filing with Coastlands Capital LP (16.51%), Coastlands Capital Partners LP (16.51%) and 2 more | 1,250,000 | 16.15% | 13G (passive) | Apr 27, 2026 |
| Domicilium Capital Partners LLC Joint filing with Daniel Simon (19.99%), Bkjlagg, LLC (14.10%) and 4 more | 854,973 | 19.99% | 13G (passive) | Jun 5, 2026 |
| Coastlands Capital Partners LP Joint filing with Coastlands Capital LP (9.99%), Coastlands Capital GP LLC (9.99%) and 2 more | 410,530 | 9.99% | 13G (passive) | Jun 10, 2026 |
| Raymond Debbane Joint filing with Invus Public Equities, L.P. (8.80%), Invus Public Equities Advisors, LLC (8.80%) and 2 more | 403,586 | 9.99% | 13G (passive) | Jun 9, 2026 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (9.90%), EcoR1 Capital Fund Qualified, L.P. (9.30%) | 403,586 | 9.90% | 13G (passive) | Jun 9, 2026 |
| Srinivas Akkaraju Joint filing with Samsara BioCapital, L.P. (5.00%), Samsara BioCapital GP, LLC (5.00%) and 2 more | 403,586 | 9.90% | 13G (passive) | Jun 10, 2026 |
| Stonepine Capital, L.P. Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine GP, LLC (9.90%) and 1 more | 403,228 | 9.90% | 13G (passive) | Jun 9, 2026 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (9.91%), Daniel Mack (9.91%) | 400,000 | 9.91% | 13G (passive) | Jun 30, 2026 |
| Aberdeen Group plc Joint filing with abrdn Inc. (9.91%) | 400,000 | 9.91% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELOX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 800,000 | 19.82% | $11.10M | New | 0.18% |
| abrdn plc | 400,000 | 9.91% | $5.55M | New | 0.01% |
| EcoR1 Capital, LLC | 400,000 | 9.91% | $5.55M | New | 0.27% |
| Samsara BioCapital, LLC | 400,000 | 9.91% | $5.55M | New | 0.46% |
| Siren, L.L.C. | 400,000 | 9.91% | $5.55M | New | 0.11% |
| Stonepine Capital Management, LLC | 397,160 | 9.84% | $5.51M | New | 3.11% |
| Vanguard Capital Management LLC | 78,680 | 1.95% | $1.09M | New | 0.00% |
| Vanguard Fiduciary Trust Co | 10,602 | 0.26% | $147.16K | New | 0.00% |
| Seven Grand Managers, LLC | 10,000 | 0.25% | $138.80K | New | 0.01% |
| Morgan Stanley | 1,544 | 0.04% | $21.43K | New | 0.00% |
| Vanguard Global Advisers, LLC | 718 | 0.02% | $9.97K | New | 0.00% |
| UBS Group AG | 637 | 0.02% | $8.84K | New | 0.00% |
| Wells Fargo & Company/Mn | 126 | 0.00% | $1.75K | New | 0.00% |
| Royal Bank of Canada | 98 | 0.00% | $1.00K | New | 0.00% |
| Pioneer Family Office, LLC | 96 | 0.00% | $1.33K | New | 0.00% |
| Altshuler Shaham Ltd | 25 | 0.00% | $347 | New | 0.00% |
| Barclays PLC | 12 | 0.00% | $167 | New | 0.00% |
| Old Point Trust & Financial Services N A | 5 | 0.00% | $69 | New | 0.00% |
| Activest Wealth Management | 4 | 0.00% | $56 | New | 0.00% |
| Citigroup Inc | 4 | 0.00% | $56 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 3M | 71.8% | 22 / 0 | 0 / 0 | 3M | 0M |
| Q1 2023 | 0 | 0M | 0.0% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q4 2022 | 1 | 0M | 0.4% | 0 / 1 | 0 / 31 | 0M | 0M |
| Q3 2022 | 32 | 0M | 7.8% | 3 / 6 | 9 / 2 | 0M | 0M |
| Q2 2022 | 32 | 0M | 8.1% | 3 / 5 | 13 / 7 | 0M | 0M |
| Q1 2022 | 36 | 0M | 9.3% | 3 / 8 | 14 / 6 | 0M | 0M |
| Q4 2021 | 39 | 0M | 10.3% | 10 / 9 | 13 / 12 | 0M | 0M |
| Q3 2021 | 41 | 0M | 10.0% | 8 / 12 | 12 / 14 | 0M | 0M |
| Q2 2021 | 47 | 0M | 10.3% | 22 / 10 | 10 / 13 | 0M | 0M |
| Q1 2021 | 38 | 0M | 5.4% | 1 / 9 | 13 / 4 | 0M | 0M |
| Q4 2020 | 41 | 0M | 5.4% | 4 / 15 | 9 / 1 | 0M | 0M |
| Q3 2020 | 38 | 0M | 5.3% | 1 / 7 | 17 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held ELOX in Q3 2023, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ELOX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 57,476 | 1.42% | $797.77K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 19,291 | 0.48% | $267.76K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 1,036 | 0.03% | $14.38K | 0.00% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 877 | 0.02% | $12.17K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sumit Aggarwal | President and CEO, Director | 1,672,756 | 41.44% | Jun 10, 2026 |
| Geno J. Germano | Director | – | – | Oct 21, 2026 |
| Nina S. Kjellson | Director | – | – | Jun 10, 2026 |
| Steven D. Rubin | Director | 14,625 | 0.36% | Jun 10, 2026 |
| Stephen W. Webster | Director | – | – | Jun 10, 2026 |
| Alan Edmund Walts | Director | 15,567 | 0.39% | Jun 10, 2026 |
| Lindsay Androski | Director | 15,750 | 0.39% | Jan 28, 2025 |
| Real Estate Fund III LP Domicilium | 10% owner | 238,422 | 5.91% | Jun 17, 2026 |
| Capital LP Coastlands | 10% owner | 0 | – | May 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Real Estate Fund III LP Domicilium 10% owner | Jun 10, 2026 | Other | +238,422 | – | – | 238,422 |
| Real Estate Fund III LP Domicilium 10% owner | Jun 10, 2026 | Other | +361,578 | – | – | 361,578 |
| Real Estate Fund III LP Domicilium 10% owner | May 27, 2026 | Other | −113,636 | – | – | 0 |
| Capital LP Coastlands 10% owner | May 27, 2026 | Other | −1,250,000 | – | – | 0 |
| Sumit Aggarwal President and CEO, Director, 10% owner | Feb 28, 2026 | Option exercise | +260,946 | $0.15 | $39.14K | 1,672,756 |
| Steven D. Rubin Director | Jan 24, 2026 | Option exercise | +1,875 | – | – | 14,625 |
| Alan Edmund Walts Director | Jan 24, 2026 | Option exercise | +1,875 | – | – | 15,567 |
| Sumit Aggarwal President and CEO, Director, 10% owner | Jan 24, 2026 | Option exercise | +15,000 | – | – | 1,411,810 |
| Sumit Aggarwal President and CEO, Director, 10% owner | Sep 19, 2025 | Award | +1,000,000 | – | – | 1,396,810 |
| Sumit Aggarwal President and CEO, Director, 10% owner | Aug 14, 2025 | Option exercise | +196,880 | – | – | 396,810 |
| Lindsay Androski Director | Jan 24, 2025 | Option exercise | +3,750 | – | – | 15,750 |
| Sumit Aggarwal Director | Jan 24, 2025 | Option exercise | +30,000 | – | – | 199,930 |
| Steven D. Rubin Director | Jan 24, 2025 | Option exercise | +3,750 | – | – | 15,750 |
| Alan Edmund Walts Director | Jan 24, 2025 | Option exercise | +3,750 | – | – | 16,692 |
| Lindsay Androski Director | Oct 16, 2024 | Award | +12,000 | – | – | 12,000 |
| Steven D. Rubin Director | Oct 16, 2024 | Award | +12,000 | – | – | 12,000 |
| Alan Edmund Walts Director | Oct 16, 2024 | Award | +12,000 | – | – | 12,942 |
| Sumit Aggarwal PRESIDENT AND CEO, Director | Oct 16, 2024 | Award | +165,000 | – | – | 169,930 |
| Vijay Modur HEAD OF R&D | Dec 1, 2021 | Option exercise | +219,326 | – | – | 219,326 |
| Vijay Modur HEAD OF R&D | Dec 1, 2021 | Tax withholding | −64,373 | $0.72 | $46.35K | 154,953 |
| Sumit Aggarwal PRESIDENT AND CEO, Director | Dec 1, 2021 | Tax withholding | −81,933 | $0.72 | $58.99K | 197,225 |
| Sumit Aggarwal PRESIDENT AND CEO, Director | Dec 1, 2021 | Option exercise | +279,158 | – | – | 279,158 |
| Alan Edmund Walts Director | Dec 1, 2021 | Option exercise | +37,695 | – | – | 37,695 |
| Daniel E. Geffken INTERIM CFO | Nov 29, 2021 | Buy | +50,000 | $0.72 | $36.00K | 50,000 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jul 30, 2021 | Option exercise | +1,563 | – | – | 33,158 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jul 30, 2021 | Tax withholding | −459 | $1.32 | $606 | 32,699 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | May 25, 2021 | Option exercise | +6,250 | – | – | 33,430 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | May 25, 2021 | Tax withholding | −1,835 | $1.39 | $2.55K | 31,595 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | May 13, 2021 | Buy | +1,280,624 | $1.35 | $1.73M | 1,791,470 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | May 13, 2021 | Buy | +2,630,487 | $1.35 | $3.55M | 3,679,797 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | May 13, 2021 | Buy | +1,422,222 | $1.35 | $1.92M | 1,989,551 |
| Management 4 G.P. (2015) Ltd. Pontifax 10% owner | May 13, 2021 | Buy | +592,592 | $1.35 | $800.00K | 616,592 |
| Tomer Kariv Director | May 13, 2021 | Buy | +592,592 | $1.35 | $800.00K | 616,592 |
| Tomer Kariv Director | May 13, 2021 | Buy | +1,422,222 | $1.35 | $1.92M | 1,989,551 |
| Tomer Kariv Director | May 13, 2021 | Buy | +2,630,487 | $1.35 | $3.55M | 3,679,797 |
| Tomer Kariv Director | May 13, 2021 | Buy | +1,280,624 | $1.35 | $1.73M | 1,791,470 |
| Rajesh B. Parekh Director | May 13, 2021 | Buy | +2,381,890 | $1.35 | $3.22M | 4,827,129 |
| Rajesh B. Parekh Director | May 13, 2021 | Buy | +84,776 | $1.35 | $114.45K | 171,807 |
| Ran Nussbaum Director | May 13, 2021 | Buy | +1,280,624 | $1.35 | $1.73M | 1,791,470 |
| Ran Nussbaum Director | May 13, 2021 | Buy | +2,630,487 | $1.35 | $3.55M | 3,679,797 |
| Ran Nussbaum Director | May 13, 2021 | Buy | +1,422,222 | $1.35 | $1.92M | 1,989,551 |
| Ran Nussbaum Director | May 13, 2021 | Buy | +592,592 | $1.35 | $800.00K | 616,592 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Apr 30, 2021 | Tax withholding | −459 | $2.18 | $1.00K | 27,180 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Apr 30, 2021 | Option exercise | +1,562 | – | – | 27,639 |
| Rajesh B. Parekh Director | Apr 1, 2021 | Award | +2,445,239 | – | – | 2,445,239 |
| Rajesh B. Parekh Director | Apr 1, 2021 | Award | +87,031 | – | – | 87,031 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Feb 25, 2021 | Tax withholding | −7,338 | $3.95 | $28.99K | 26,077 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Feb 25, 2021 | Option exercise | +25,000 | – | – | 33,415 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Feb 25, 2021 | Tax withholding | −15,360 | $3.95 | $60.67K | 44,629 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Feb 25, 2021 | Option exercise | +50,000 | – | – | 59,989 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jan 30, 2021 | Tax withholding | −542 | $3.44 | $1.86K | 8,415 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jan 30, 2021 | Option exercise | +1,563 | – | – | 8,957 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Jan 30, 2021 | Tax withholding | −643 | $3.44 | $2.21K | 9,989 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Jan 30, 2021 | Option exercise | +1,875 | – | – | 10,632 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Oct 30, 2020 | Tax withholding | −625 | $2.53 | $1.58K | 8,757 |
| Gregory C. Williams CHIEF EXECUTIVE OFFICER, Director | Oct 30, 2020 | Option exercise | +1,875 | – | – | 9,382 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Oct 30, 2020 | Tax withholding | −459 | $2.53 | $1.16K | 7,394 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Oct 30, 2020 | Option exercise | +1,562 | – | – | 7,853 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jul 30, 2020 | Tax withholding | −459 | $2.84 | $1.30K | 6,291 |
| Neil S. Belloff COO, GENERAL COUNSEL &CORP SEC | Jul 30, 2020 | Option exercise | +1,563 | – | – | 6,750 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Eloxx Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,418 shares on Sep 14, 2026 over the last 90 days.
See a number that looks wrong?